
Supplementary Online Content

Arjona-Sánchez A, Espinosa-Redondo E, Gutiérrez-Calvo A, et al. Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colon cancer: a phase 3 randomized clinical trial. *JAMA Surg.* Published online April 26, 2023. doi:10.1001/jamasurg.2023.0662

- **eFigure 1.** Three-Year Disease-Free Survival Rates in the HIPEC Group and Comparator Group
- eFigure 2. Recurrence Sites in the HIPEC Group and Control Group
- **eFigure 3.** Three-Year Overall Survival Rates in the HIPEC Group and Comparator Group
- eFigure 4. Three-Year Locoregional Control Rate in the HIPEC Group and Comparator Group


This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure 1. Three-year disease-free survival rates in the HIPEC group and comparator group.




HIPEC=hyperthermic intraperitoneal chemotherapy. HR=hazard ratio. Cl=confidence interval.

eFigure 2. Recurrence sites in the HIPEC group and control group.




HIPEC=hyperthermic intraperitoneal chemotherapy.

eFigure 3. Three-year overall survival rates in the HIPEC group and comparator group.



HIPEC=hyperthermic intraperitoneal chemotherapy. HR=hazard ratio. Cl=confidence interval.

eFigure 4. Three-year locoregional control rate in the HIPEC group and comparator group.



HIPEC=hyperthermic intraperitoneal chemotherapy. HR=hazard ratio. CI=confidence interval.